Recent advances in understanding the genetic etiology of congenital heart disease

Current Opinion in Pediatrics

Volumn 11, Issue 5, 1999, Pages 437-443

  Goldmuntz, Elizabeth ^a  

^a CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALAGILLE SYNDROME; CHROMOSOME DELETION; CONGENITAL HEART DISEASE; GENE LOCUS; GENOTYPE; HEART ARRHYTHMIA; HEART ATRIUM SEPTUM DEFECT; HEART DILATATION; HETEROTAXY SYNDROME; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; LONG QT SYNDROME; PHENOTYPE; PRIORITY JOURNAL; REVIEW;

ARRHYTHMIA; CARDIOMYOPATHY, DILATED; CARDIOMYOPATHY, HYPERTROPHIC; HEART DEFECTS, CONGENITAL; HUMANS;

EID: 0032826441     PISSN: 10408703     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008480-199910000-00012     Document Type: Review

References (52)

1. Watkins H, McKenna WJ, Thierfelder L, Suk HJ, Anan R, O'Donoghue A, et al.: Mutations in the genes for cardiac troponin T and α-tropomyosin in hypertrophic cardiomyopathy. N Engl J Med 1995, 332:1058-1064.
2. Niimura H, Bachinski LL, Sangwatanaroj S, Watkins H, Chudley AE, McKenna W, et al.: Mutations in the gene for cardiac myosin-binding protein C and late-onset familial hypertrophic cardiomyopathy. N Engl J Med 1998, 338:1248-1257.
3. Seidman CE, Seidman JG: Molecular genetic studies of familial hypertrophic cardiomyopathy. Basic Res Cardiol 1998, 93(suppl 3):13-16.
4. Maron BJ, Moller JH, Seidman CE, Vincent GM, Dietz HC, Moss AJ, et al.: Impact of laboratory molecular diagnosis on contemporary diagnostic criteria for genetically transmitted cardiovascular disease: hypertrophic cardiomyopathy, long-QT syndrome, and Marfan syndrome. Circulation 1998, 98:1460-1471. In this article, the authors review the clinical and molecular genetics of hypertrophic cardiomyopathy and also discuss the practical and ethical issues of molecular diagnosis for clinical purposes.
5. Watkins H, Rosenzweig A, Hwang DS, Levi T, McKenna W, Seidman CE, Seidman JG: Characteristics and prognostic implications of myosin missense mutations in familial hypertrophic cardiomyopathy. N Engl J Med 1992, 326:1108-1114.
6. Epatein ND, Cohn GM, Cyran F, Fananapazir L: Differences in clinical expression of hypertrophic cardiomyopathy associated with two distinct mutations in the β-myosin heavy chain gene. Circulation 1992, 86:345-352.
7. Marian AJ, Roberts R: Recent advances in the molecular genetics of hypertrophic cardiomyopathy. Circulation 1995, 92:1336-1347.
8. Moolman JC, Corfield VA, Posen B, Ngumbela K, Seidman C, Brink PA, Watkins H: Sudden death due to troponin T mutations. J Am Coll Cardiol 1997, 29:549-555.
9. Charron P, Dubourg O, Desnos M, Bennaceur M, Carrier L, Camproux A-C, et al.: Clinical features and prognostic implications of familial hypertrophic cardiomyopathy related to the cardiac myosin-binding protein C gene. Circulation 1998, 97:2230-2236.
10. Kelly DP, Strauss AW: Mechanisms of disease. N Engl J Med 1994, 330:913-919.
11. Beggs AH: Dystrophinopathy, the expanding phenotype: dystrophin abnormalities in X-linked dilated cardiomyopathy. Circulation 1997, 95:2344-2347.
12. Bione S, D'Adamo P, Maestrini E, Gedeon AK, Bolhuis PA, Toniolo D: A novel X-linked gene, G4.5, is responsible for Barth syndrome. Nature Genet 1996, 12:385-389.
13. D'Adamo PD, Fassone L, Gedeon A, Janssen EAM, Bione S, Bolhuis PA, et al.: The X-linked gene G4.5 is responsible for different infantile dilated cardiomyopathies. Am J Hum Genet 1997, 61:862-867.
14. Bleyl SB, Mumford BR, Thompson V, Carey JC, Pysher TJ, Chin TK, Ward K: Neonatal, lethal noncompaction of the left ventricular myocardium is allelic with Barth syndrome. Am J Hum Genet 1997, 61:868-872.
15. Siu BL, Niimura H, Osborne JA, Fatkin D, MacRae C, Solomon S, et al.: Familial dilated cardiomyopathy locus maps to chromosome 2q31. Circulation 1999, 99:1022-1026.
16. Olson TM, Michels VV, Thibodeau SN, Tai Y-S, Keating MT: Actin mutations in dilated cardiomyopathy, a heritable form of heart failure. Science 1998, 280:750-752. These investigators hypothesized that actin dysfunction would result in heart failure and that mutations in actin might cause dilated cardiomyopathy. They identified missense mutations of actin in two unrelated families with dilated cardiomyopathy. This report is the first to identify an autosomal disease-related gene (compared with an X-linked gene).
17. Nezu J-I, Tamai I, Oku A, Ohashi R, Yabuuchi H, Hashimoto N, et al.: Primary systemic carnitine deficiency is caused by mutations in a gene encoding sodium ion-dependent carnitine transporter. Nat Genet 1999, 21:91-94.
18. Grunig E, Tasman JA, Kucherer H, Franz W, Kubler W, Katus HA: Frequency and phenotypes of familial dilated cardiomyopathy. J Am Coll Cardiol 1998, 31:186-194.
19. Baig MK, Goldman JH, Caforio ALP, Coonar AS, Keeling PJ, McKenna WJ: Familial dilated cardiomyopathy: cardiac abnormalities are common in asymptomatic relatives and may represent early disease. J Am Coll Cardiol 1998, 31:195-201. The investigators prospectively examined asymptomatic relatives of index cases with dilated cardiomyopathy for echocardiographic changes. Nearly one third of relatives were found to have echocardiographic changes; some went on to develop dilated cardiomyopathy. This study emphasizes that dilated cardiomyopathy is more frequently familial than previously considered. The results lead to unanswered questions about the appropriate screening of family members when an index case is first diagnosed.
20. Roden DM, Lazzara R, Rosen M, Schwartz PJ, Towbin J, Vincent GM: Multiple mechanisms in the long-QT syndrome: current knowledge, gaps and future directions. Circulation 1996, 94:1996-2012.
21. Wang Q, Chen Q, Li H, Towbin J: Molecular genetics of long QT syndrome from genes to patients. Curr Opin Cardiol 1997, 12:310-320.
22. Priori SG, Barhanin J, Hauer RNW, Haverkamp W, Jongsma HJ, Kleber AG, et al.: Genetic and molecular basis of cardiac arrhythmias: impact on clinical management: parts I and II. Circulation 1999, 99:518-528.
23. Vincent GM, Timothy KW, Leppert M, Keating M: The spectrum of symptoms and QT intervals in carriers of the gene for the long-QT syndrome. N Engl J Med 1992, 327:846-852.
24. Priori SG, Napolitano C, Schwartz PJ: Low penetrance in the long-QT syndrome. Circulation 1999, 99:529-533. In this study, the authors found that 33% of asymptomatic relatives (with normal electrocardiograms) of "sporadic" cases with the long QT syndrome carried the mutation. Thus, the penetrance of the disease is lower than previously considered. The investigators also highlight the inadequacy of clinical diagnosis alone in the absence of molecular confirmation. However, they do not fully address the present unavailability and inadequacy of molecular diagnostic tests or the dilemma of treatment for the older, asymptomatic mutation carrier.
25. Moss AJ, Zareba W, Benhorin J, Locati EH, Hall WJ, Robinson JL, et al.: ECG T-wave patterns in genetically distinct forms of the hereditary long QT syndrome. Circulation 1995, 92:2929-2934.
26. Zareba W, Moss AJ, Schwartz PJ, Vincent GM, Robinson JL, Priori SG, et al.: Influence of the genotype on the clinical course of the long-QT syndrome. N Engl J Med 1998, 339:960-965. The authors of this study compare the frequency of cardiac events within a large cohort of patients with long QT syndrome based on the length of their QTc and specific genotype. The patients whose electrocardiogram revealed a longer QTc were at greater risk for cardiac events, whereas patients with mutations in KvLQT1 or HERG were at greater risk for earlier cardiac events, but all three genotypes (KvLQT1, HERG, and SCN5A) had the same cumulative mortality. The strength of this article lies in the large numbers of patients examined, but it should be remembered that this cohort comes from only 38 families who share a more common genetic background than an equivalent number of unrelated people. The genetic background could also influence outcome.
27. 1). J Am Coll Cardiol 1999, 33:327-332. Although this study includes only 11 families, it confirms previous work that suggested that the stimuli leading to a cardiac event varied with genotype. Presumably, larger studies investigating this specific question also will be forth-coming.
28. + channel blockade and to increases in heart rate. Circulation 1995, 92:3381-3386.
29. Brink PA, Ferreira A, Moolman JC, Weymar HW, van der Merwe P-L, Corfield VA: Gene for progressive familial heart block type 1 maps to chromosome 19q13. Circulation 1995, 91:1633-1640.
30. Ahmad F, Li D, Karibe A, Gonzalez O, Tapscott T, Hill R, et al.: Localization of a gene responsible for arrhythmogenic right ventricular dysplasia to chromosome 3p23. Circulation 1998, 98:2791-2795.
31. Brugada R, Tapscott T, Czemuszewicz GZ, Marian AJ, Iglesias A, Mont L, et al.: Identification of a genetic locus for familial atrial fibrillation. N Engl J Med 1997, 336:905-911.
32. Chen Q, Kirsch GE, Zhang D, Brugada R, Brugada J, Brugada P, et al.: Genetic basis and molecular mechanism for idiopathic ventricular fibrillation. Nature 1998, 392:293-296. These investigators identify the first disease-related gene in a unique patient population with asymptomatic electrocardiogram changes and ventricular fibrillation. They demonstrate that although the disease gene is the same as that in some patients with long QT syndrome, the families with ventricular fibrillation have a unique syndrome. This report contributes to the evidence that familial arrhythmias are caused by mutations in ion channels.
33. Bonnet D, Pelet A, Legeai-Mallet L, Sidi D, Mathieu M, Parent P, et al.: A gene for Holt-Oram syndrome maps to the distal long arm of chromosome 12. Nature Genet 1994, 6:405-408.
34. Terrett JA, Newbury-Ecob R, Cross GS, Fenton I, Raeburn JA, Young ID, Brook JD: Holt-Oram syndrome is a genetically heterogeneous disease with one locus mapping to human chromosome 12q. Nature Genet 1994, 6:401-404.
35. Li QY, Newbury-Ecob RA, Terrett JA, Wilson DI, Curtis ARJ, Yi CH, et al.: Holt-Oram syndrome is caused by mutations in TBX5, a member of the Brachyury (T) gene family. Nature Genet 1997, 15:21-29.
36. Basson CT, Bachinsky DR, Lin RC, Levi T, Elkins JA, Soults J, et al.: Mutations in human cause limb and cardiac malformation in Holt-Oram syndrome. Nature Genet 1997, 15:30-35.
37. Benson DW, Sharkey A, Fatkin D, Lang P, Basson CT, McDonough B, et al.: Reduced penetrance, variable expressivity, and genetic heterogeneity of familial atrial septal defects. Circulation 1998, 97:2043-2048.
38. Schott JJ, Benson DW, Basson CT, Pease W, Silberbach GM, Moak JP, et al.: Congenital heart disease caused by mutations in the transcription factor NkX2-5. Science 1998, 281:108-111. In this study, the authors use the classic techniques of linkage analysis and candidate gene screening to identify the first disease-related gene for nonsyndromic congenital heart disease, ie, atrial septal defects with conduction abnormalities.
39. Thomas JA, Graham JM: Chromosome 22q11 deletion syndrome: an update and review for the primary pediatrician. Clin Pediatr 1997, 36:253-266.
40. Emanuel BS, Budarf ML, Scambler PJ: The genetic basis of conotruncal cardiac defects: the chromosome 22q11.2 deletion. In Heart Development, edn 26. Edited by Harvey RP, Rosenthal N. San Diego: Academic Press; 1999:463-478.
41. Ryan AK, Goodship JA, Wilson DI, Philip N, Levy A, Seidel H, et al.: Spectrum of clinical features associated with interstitial chromosome 22q11 deletions: a European collaborative study. J Med Genet 1997, 34:798-804.
42. McDonald-McGinn DM, LaRossa D, Goldmuntz E, Sullivan K, Eicher P, Gerdes M, et al.: The 22q11.2 deletion: screening, diagnostic workup, and outcome of results: report on 181 patients. Genet Testing 1997, 1:99-108.
43. Goldmuntz E, Clark BJ, Mitchell LE, Jawad AF, Cuneo BF, Reed L, et al.: Frequency of 22q11 deletions in patients with conotruncal defects. J Am Coll Cardiol 1998, 32:492-498.
44. O'Donnell H, McKeown C, Gould C, Morrow B, Scambler P: Detection of an atypical 22q11 deletion that has no overlap with the DiGeorge syndrome critical region. Am J Hum Genet 1997, 60:1544-1548.
45. Kurahashi H, Tsuda E, Kohama R, Nakayama T, Masuno M, Imaizumi K, et al.: Another critical region for deletion of 22q11: a study of 100 patients. Am J Med Genet 1997, 72:180-185.
46. Rauch A, Pfeiffer RA, Leipold G, Singer H, Tigges M, Hofbeck M: A novel 22q11.2 microdeletion in DiGeorge syndrome. Am J Hum Genet 1999, 64:659-667.
47. Yamagishi H, Garg V, Matsuoka R, Thomas T, Srivastava D: A molecular pathway revealing a genetic basis for human cardiac and craniofacial defects. Science 1999, 283:1158-1161. In this study, the authors report on a unique patient with an atypical deletion of 22q11 that provides some evidence that the gene UFDL1 may be disease-related in the 22q11 deletion syndrome. Evidence supporting this hypothesis includes expression studies of UFDL1 in the mouse embryo and experiments implicating UFDL1 in the same developmental pathway as d-Hand. Most investigators in this field do not consider this hypothesis to be definitive and believe further investigations are required.
48. Srivastava D: HAND proteins: molecular mediators of cardiac development and congenital heart disease. Trends Cardiovasc Med 1999, 9:11-18.
49. Li L, Krantz ID, Deng Y, Genin A, Banta AB, Collins CC, et al.: Alagille syndrome is caused by mutations in human Jagged1, which encodes a ligand for Notch1. Nat Genet 1997, 16:243-251.
50. Oda T, Elkahloun AG, Pike BL, Okajima K, Krantz ID, Genin A, et al.: Mutations in the human Jagged1 gene are responsible for Alagille syndrome. Nat Genet 1997, 16:235-242.
51. Krantz I, Smith R, Colliton RP, Tinkel H, Zackai EH, Piccoli DA, et al.: Jagged1 mutations in patients ascertained with isolated congenital heart defects. Am J Med Genet 1999, 84:56-60.
52. Gebbia M, Ferrero GB, Pilia G, Bassi MT, Aylsworth AS, Penman-Splitt M, et al.: X-linked situs abnormalities result from mutations in ZIC3. Nature Genet 1997, 17:305-308.